For immediate release: 07:00 15 October 2007
VALIRX PLC
("ValiRx")
License Agreement
ValiRx (AIM: VAL), the cancer therapeutics company, is pleased to announce that
it has signed a full license agreement with Chroma Therapeutics Ltd ("Chroma")
to commercialise a non-invasive diagnostic technology patent developed by
Chroma. The technology identifies epigenetic signal changes, in particular
changes to the histone code, which occur in cancer related illnesses.
ValiRx believes this technology, called Nucleosomics1, has the potential to
complement ValiRx's existing cancer diagnostics technology, HyperGenomics2, to
create a non-invasive, mass screening, cancer diagnostics package that can
deliver early stage diagnosis, specific diagnosis, prognosis, evaluation and
therapeutic strategy.
The ongoing testing and development of the Nucleosomics technology alongside
HyperGenomics will be carried out by ValiBIO S.A., ValiRx's recently formed
Belgium subsidiary.
Under the terms of the agreement, ValiRx will pay Chroma royalties on any
future sales resulting from commercialisation of the Nucleosomics technology.
Dr Satu Vainikka, CEO of ValiRx, commented:
"Put together, we believe that these technologies have the potential to form a
mass screening, non-invasive cancer diagnostic and management package. Further,
as both technologies are centred on epigenomics, we have the ability to develop
and commercialise them jointly using existing resources and partnerships."
Ian Nicholson, CEO of Chroma, added:
"We are pleased to have partnered this programme with, in our opinion, a
diagnostics specialist who has the skill base to fully exploit its potential as
a new approach to cancer diagnostics."
Notes to editor
1. NucleosomicsTM
Nucleosmics is a non-invasive (blood) test for early cancer diagnosis based on
epigenetic signal changes associated with malignancy.
The control of gene expression is determined by a number of different
epigenetic regulatory mechanisms. Paramount amongst these is the chromatin
environment surrounding the gene and key covalent modifications (including
acetylation, methylation, phosphorilation and others) to the histone proteins
associated with the nucleosomes of the gene. This is often referred to as the
histone code.
Disruption of the normal histone code is associated with aberrant gene
expression and malignant transformation and these alterations are the basis of
Nucleosomics.
Nucleosomics is non-invasive. Intact nucleosomes derived from tumour chromatin
are found in the blood of cancer patients, but not in healthy individuals.
These cell-free nucleosomes can be analysed for histone code modifications. The
presence in the blood of nucleosomes associated with particular histone
modifications and/or gene sequences can therefore be used to diagnose the
particular cancer.
2. HyperGenomics
Developed by Chronos Therapeutics, the HyperGenomics technology characterises
cancerous and normal cells by mapping the open areas of chromatin on a
chromosome using a patented PCR-based method.
About ValiRx plc
ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds stakes in Cronos and Morphogenesis Inc;
* Cronos holds licenses to two innovative and potentially market changing
technologies, GeneICE and HyperGenomics;
* Morphogenesis Inc. is developing a portfolio of cell therapy products for
the treatment of chronic disorders. Its most advanced product, being
ImmuneFxâ„¢ for which it recently received a patent from the US patent
office.
ValiRx is headquartered in London, England. Further information can be found at
www.valirx.com
About Chroma Therapeutics
Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development
company focused on building a broad pipeline of first- or best-in-class
treatments for haematological and solid tumours. Chroma is backed by a number
of leading specialist investors, including Abingworth, Essex Woodlands, Gilde,
Nomura Phase4 and The Wellcome Trust.
More information about Chroma can be found at www.chromatherapeutics.com.
Contact Details:
ValiRx Plc WH Ireland Chroma Therapeutics GTH Communications
Dr Satu Vainikka David Youngman Ian Nicholson / Toby Hall / Jade
Richard Bungay Mamarbachi
+44 (0) 203 008 +44 (0) 161 832 +44 (0)1235 829 120 +44 (0) 20 7153 8035
4416 2174
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.